MDSpire - Takeaway
Clinical Guidelines
Commentary & Perspectives

Industry Insights: Genomic Testing for Early-Stage Breast Cancer

William Audeh, Chief Medical Officer at Agendia, discusses recent data supporting genomic testing results in guiding clinical decision-making

  • March 27, 2026

  • 8 min

Share

  • 1

    Genomic assays focus on tumor biology for treatment decisions.

  • 2

    MINDACT trial shows some patients can skip chemotherapy.

  • 3

    Genomic profiling aids surgical strategy choices.

  • 4

    HR+/HER2- tumors may show basal-type through genomic tests.

  • 5

    Timely genomic results improve treatment planning.

Original Source(s)

Industry Insights: Genomic Testing for Early-Stage Breast Cancer

  • March 27, 2026

Related Content

Recipients Named for the 2026 Pezcoller Foundation–AACR International Award

The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas R. Lowy, MD, and John T. Schi...

AI As Collaborator in Cancer Research and in Clinical Care

Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identif...

AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?

The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New E...